ID   MCF-10A
AC   CVCL_0598
SY   MCF 10A; MCF.10A; MCF10A; MCF10-A; MCF10a; MCF-10 Attached; Michigan Cancer Foundation-10A
DR   BTO; BTO:0001939
DR   CLO; CLO_0007599
DR   EFO; EFO_0001200
DR   MCCL; MCC:0000305
DR   AddexBio; C0006015/4976
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-TABM-157
DR   ATCC; CRL-10317
DR   BCRJ; 0161
DR   BioGRID_ORCS_Cell_line; 40
DR   BioSample; SAMN03471375
DR   cancercelllines; CVCL_0598
DR   CCRID; 1101HUM-PUMC000406
DR   ChEMBL-Cells; CHEMBL3307364
DR   ChEMBL-Targets; CHEMBL614321
DR   CLS; 305026
DR   Cosmic; 1136376
DR   Cosmic; 1176649
DR   Cosmic; 2318371
DR   Cosmic; 2560254
DR   DepMap; ACH-001357
DR   EGA; EGAS00001000610
DR   GEO; GSM50033
DR   GEO; GSM155217
DR   GEO; GSM320171
DR   GEO; GSM350543
DR   GEO; GSM498022
DR   GEO; GSM498026
DR   GEO; GSM756371
DR   GEO; GSM845395
DR   GEO; GSM844584
DR   GEO; GSM1053724
DR   GEO; GSM1172973
DR   GEO; GSM1172882
DR   GEO; GSM1238116
DR   GEO; GSM1328939
DR   GEO; GSM1328940
DR   GEO; GSM1328941
DR   GEO; GSM2258704
DR   GEO; GSM2258705
DR   GEO; GSM2258706
DR   GEO; GSM2258707
DR   GEO; GSM2258708
DR   GEO; GSM2258709
DR   GEO; GSM2258710
DR   GEO; GSM2258711
DR   GEO; GSM2258712
DR   GEO; GSM2258713
DR   GEO; GSM2258714
DR   GEO; GSM2258715
DR   GEO; GSM2258716
DR   GEO; GSM2258717
DR   GEO; GSM2258718
DR   GEO; GSM2258719
DR   GEO; GSM2258720
DR   GEO; GSM2258721
DR   GEO; GSM2258944
DR   GEO; GSM2258945
DR   GEO; GSM2258946
DR   GEO; GSM2862786
DR   GEO; GSM2862787
DR   GEO; GSM2862788
DR   IARC_TP53; 24292
DR   IBRC; C10788
DR   KCB; KCB 2014066YJ
DR   LINCS_HMS; 50583
DR   Lonza; 131
DR   MetaboLights; MTBLS401
DR   NCBI_Iran; C609
DR   PharmacoDB; MCF10A_891_2019
DR   PRIDE; PXD000309
DR   PRIDE; PXD000593
DR   PRIDE; PXD000691
DR   PRIDE; PXD003370
DR   PRIDE; PXD005339
DR   PRIDE; PXD008222
DR   PRIDE; PXD009668
DR   Progenetix; CVCL_0598
DR   PubChem_Cell_line; CVCL_0598
DR   TOKU-E; 2378
DR   Wikidata; Q54904280
RX   DOI=10.1016/B978-0-12-333530-2.50009-5;
RX   Patent=US5436152;
RX   PubMed=1975513;
RX   PubMed=12661003;
RX   PubMed=15153330;
RX   PubMed=15375546;
RX   PubMed=16271952;
RX   PubMed=17157791;
RX   PubMed=17334996;
RX   PubMed=19582160;
RX   PubMed=20169162;
RX   PubMed=22414580;
RX   PubMed=24009699;
RX   PubMed=24094812;
RX   PubMed=24162158;
RX   PubMed=24176112;
RX   PubMed=24262153;
RX   PubMed=24389870;
RX   PubMed=25485619;
RX   PubMed=25877200;
RX   PubMed=25892236;
RX   PubMed=25960936;
RX   PubMed=26055192;
RX   PubMed=26218769;
RX   PubMed=26589293;
RX   PubMed=28196595;
RX   PubMed=28287265;
RX   PubMed=28596718;
RX   PubMed=28889351;
RX   PubMed=29273624;
RX   PubMed=29444910;
RX   PubMed=29561695;
RX   PubMed=30787054;
RX   PubMed=32782317;
RX   PubMed=34238275;
CC   Group: Patented cell line.
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: JWGray breast cancer cell line panel.
CC   Part of: ICBP43 breast cancer cell line panel.
CC   Part of: MD Anderson Cell Lines Project.
CC   Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-10317.
CC   Doubling time: 97.4 hours (PubMed=24389870); 20 hours (PubMed=34238275); 26.74 hours (JWGray panel).
CC   HLA typing: A*01:01,33:01; B*40:01,55:01; C*03:03,07:02; DQA1*02:01,03:02; DQB1*03:05,03:05; DRB1*04:02,11:44 (PubMed=25960936).
CC   HLA typing: A*01:01,33:01; B*40:01,55:01; C*03:03,07:02; DRB1*01:01,13:10 (PubMed=26589293).
CC   Microsatellite instability: Stable (MSS) (PubMed=12661003).
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=17334996).
CC   Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (PubMed=17334996).
CC   Omics: Array-based CGH.
CC   Omics: CNV analysis.
CC   Omics: Deep proteome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Exosome proteome analysis.
CC   Omics: Glycoproteome analysis by proteomics.
CC   Omics: H2BK120ub ChIP-seq epigenome analysis.
CC   Omics: H3K23ac ChIP-seq epigenome analysis.
CC   Omics: H3K27ac ChIP-seq epigenome analysis.
CC   Omics: H3K27me3 ChIP-seq epigenome analysis.
CC   Omics: H3K36me3 ChIP-seq epigenome analysis.
CC   Omics: H3K4me1 ChIP-seq epigenome analysis.
CC   Omics: H3K4me3 ChIP-seq epigenome analysis.
CC   Omics: H3K79me2 ChIP-seq epigenome analysis.
CC   Omics: H3K9ac ChIP-seq epigenome analysis.
CC   Omics: H3K9me3 ChIP-seq epigenome analysis.
CC   Omics: H4K8ac ChIP-seq epigenome analysis.
CC   Omics: Metabolome analysis.
CC   Omics: N-glycan profiling.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: In situ; Breast, epithelium; UBERON=UBERON_0008359.
ST   Source(s): AddexBio=C0006015/4976; ATCC=CRL-10317; CCRID; Technion Genomics Center BCF; PubMed=25877200; PubMed=28889351; PubMed=29444910
ST   Amelogenin: X
ST   CSF1PO: 10,12
ST   D10S1248: 14,16
ST   D12S391: 16,20 (Technion Genomics Center BCF)
ST   D12S391: 17,20 (CCRID)
ST   D13S317: 8,9
ST   D16S539: 11,12
ST   D18S51: 18,19
ST   D19S433: 13,15
ST   D1S1656: 16.3,17.3
ST   D21S11: 28,30
ST   D22S1045: 11,18
ST   D2S1338: 21,26
ST   D2S441: 11,14
ST   D3S1358: 14,18
ST   D5S818: 10,13
ST   D6S1043: 12,18
ST   D7S820: 10,11
ST   D8S1179: 14,16
ST   FGA: 22,24
ST   Penta D: 10,12
ST   Penta E: 13,14
ST   TH01: 8,9.3
ST   TPOX: 9,11
ST   vWA: 15,17
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_3633 ! MCF-10F
SX   Female
AG   36Y
CA   Spontaneously immortalized cell line
DT   Created: 04-04-12; Last updated: 02-05-24; Version: 45
RX   DOI=10.1016/B978-0-12-333530-2.50009-5;
RA   Leibovitz A.;
RT   "Cell lines from human breast.";
RL   (In) Atlas of human tumor cell lines; Hay R.J., Park J.-G., Gazdar A.F. (eds.); pp.161-184; Academic Press; New York (1994).
RX   Patent=US5436152;
RA   Soule H.D., McGrath C.M.;
RT   "Immortal human mammary epithelial cell lines.";
RL   Patent number US5436152, 25-Jul-1995.
RX   PubMed=1975513;
RA   Soule H.D., Maloney T.M., Wolman S.R., Peterson W.D. Jr., Brenz R.,
RA   McGrath C.M., Russo J., Pauley R.J., Jones R.F., Brooks S.C. Jr.;
RT   "Isolation and characterization of a spontaneously immortalized human
RT   breast epithelial cell line, MCF-10.";
RL   Cancer Res. 50:6075-6086(1990).
RX   PubMed=12661003; DOI=10.1002/gcc.10196;
RA   Seitz S., Wassmuth P., Plaschke J., Schackert H.K., Karsten U.,
RA   Santibanez-Koref M.F., Schlag P.M., Scherneck S.;
RT   "Identification of microsatellite instability and mismatch repair gene
RT   mutations in breast cancer cell lines.";
RL   Genes Chromosomes Cancer 37:29-35(2003).
RX   PubMed=15153330; DOI=10.1593/neo.3292;
RA   Watts G.S., Oshiro M.M., Junk D.J., Wozniak R.J., Watterson S.J.,
RA   Domann F.E., Futscher B.W.;
RT   "The acetyltransferase p300/CBP-associated factor is a p53 target gene
RT   in breast tumor cells.";
RL   Neoplasia 6:187-194(2004).
RX   PubMed=15375546; DOI=10.3892/ijo.25.4.961;
RA   Peng X.-J., Yun D.-R., Christov K.;
RT   "Breast cancer progression in MCF10A series of cell lines is
RT   associated with alterations in retinoic acid and retinoid X receptors
RT   and with differential response to retinoids.";
RL   Int. J. Oncol. 25:961-971(2004).
RX   PubMed=16271952; DOI=10.1016/j.cancergencyto.2005.04.019;
RA   Cowell J.K., LaDuca J., Rossi M.R., Burkhardt T., Nowak N.J.,
RA   Matsui S.-i.;
RT   "Molecular characterization of the t(3;9) associated with
RT   immortalization in the MCF10A cell line.";
RL   Cancer Genet. Cytogenet. 163:23-29(2005).
RX   PubMed=17157791; DOI=10.1016/j.ccr.2006.10.008;
RA   Neve R.M., Chin K., Fridlyand J., Yeh J., Baehner F.L., Fevr T.,
RA   Clark L., Bayani N., Coppe J.-P., Tong F., Speed T., Spellman P.T.,
RA   DeVries S., Lapuk A., Wang N.J., Kuo W.-L., Stilwell J.L., Pinkel D.,
RA   Albertson D.G., Waldman F.M., McCormick F., Dickson R.B.,
RA   Johnson M.D., Lippman M.E., Ethier S.P., Gazdar A.F., Gray J.W.;
RT   "A collection of breast cancer cell lines for the study of
RT   functionally distinct cancer subtypes.";
RL   Cancer Cell 10:515-527(2006).
RX   PubMed=17334996; DOI=10.1002/gcc.20438;
RA   Jonsson G., Staaf J., Olsson E., Heidenblad M.,
RA   Vallon-Christersson J., Osoegawa K., de Jong P.J., Oredsson S.M.,
RA   Ringner M., Hoglund M., Borg A.;
RT   "High-resolution genomic profiles of breast cancer cell lines assessed
RT   by tiling BAC array comparative genomic hybridization.";
RL   Genes Chromosomes Cancer 46:543-558(2007).
RX   PubMed=19582160; DOI=10.1371/journal.pone.0006146;
RA   Kao J., Salari K., Bocanegra M., Choi Y.-L., Girard L., Gandhi J.,
RA   Kwei K.A., Hernandez-Boussard T., Wang P., Gazdar A.F., Minna J.D.,
RA   Pollack J.R.;
RT   "Molecular profiling of breast cancer cell lines defines relevant
RT   tumor models and provides a resource for cancer gene discovery.";
RL   PLoS ONE 4:E6146-E6146(2009).
RX   PubMed=20169162; DOI=10.1371/journal.pone.0009201;
RA   Kadota M., Yang H.H., Gomez B.P., Sato M., Clifford R.J., Meerzaman D.,
RA   Dunn B.K., Wakefield L.M., Lee M.P.;
RT   "Delineating genetic alterations for tumor progression in the MCF10A
RT   series of breast cancer cell lines.";
RL   PLoS ONE 5:E9201-E9201(2010).
RX   PubMed=22414580; DOI=10.1158/0008-5472.CAN-11-3711;
RA   Geiger T., Madden S.F., Gallagher W.M., Cox J., Mann M.;
RT   "Proteomic portrait of human breast cancer progression identifies
RT   novel prognostic markers.";
RL   Cancer Res. 72:2428-2439(2012).
RX   PubMed=24009699; DOI=10.1371/journal.pone.0072704;
RA   Liu X., Nie H., Zhang Y.-B., Yao Y.-F., Maitikabili A., Qu Y.-P.,
RA   Shi S.-L., Chen C.-Y., Li Y.;
RT   "Cell surface-specific N-glycan profiling in breast cancer.";
RL   PLoS ONE 8:E72704-E72704(2013).
RX   PubMed=24094812; DOI=10.1016/j.ccr.2013.08.020;
RA   Timmerman L.A., Holton T., Yuneva M., Louie R.J., Padro M., Daemen A.,
RA   Hu M., Chan D.A., Ethier S.P., van 't Veer L.J., Polyak K.,
RA   McCormick F., Gray J.W.;
RT   "Glutamine sensitivity analysis identifies the xCT antiporter as a
RT   common triple-negative breast tumor therapeutic target.";
RL   Cancer Cell 24:450-465(2013).
RX   PubMed=24162158; DOI=10.1007/s10549-013-2743-3;
RA   Prat A., Karginova O., Parker J.S., Fan C., He X.-P., Bixby L.M.,
RA   Harrell J.C., Roman E., Adamo B., Troester M.A., Perou C.M.;
RT   "Characterization of cell lines derived from breast cancers and normal
RT   mammary tissues for the study of the intrinsic molecular subtypes.";
RL   Breast Cancer Res. Treat. 142:237-255(2013).
RX   PubMed=24176112; DOI=10.1186/gb-2013-14-10-r110;
RA   Daemen A., Griffith O.L., Heiser L.M., Wang N.J., Enache O.M.,
RA   Sanborn Z., Pepin F., Durinck S., Korkola J.E., Griffith M., Hur J.S.,
RA   Huh N., Chung J., Cope L., Fackler M.J., Umbricht C.B., Sukumar S.,
RA   Seth P., Sukhatme V.P., Jakkula L.R., Lu Y.-L., Mills G.B., Cho R.J.,
RA   Collisson E.A., van 't Veer L.J., Spellman P.T., Gray J.W.;
RT   "Modeling precision treatment of breast cancer.";
RL   Genome Biol. 14:R110.1-R110.14(2013).
RX   PubMed=24262153; DOI=10.1016/j.jprot.2013.11.006;
RA   Yen T.-Y., Haste N., Timpe L.C., Litsakos-Cheung C., Yen R.,
RA   Macher B.A.;
RT   "Using a cell line breast cancer progression system to identify
RT   biomarker candidates.";
RL   J. Proteomics 96:173-183(2014).
RX   PubMed=24389870; DOI=10.1038/srep03576;
RA   Strauch M., Ludke A., Munch D., Laudes T., Galizia C.G.,
RA   Martinelli E., Lavra L., Paolesse R., Ulivieri A., Catini A.,
RA   Capuano R., Di Natale C.;
RT   "More than apples and oranges -- detecting cancer with a fruit fly's
RT   antenna.";
RL   Sci. Rep. 4:3576-3576(2014).
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
RX   PubMed=25892236; DOI=10.1016/j.celrep.2015.03.050;
RA   Lawrence R.T., Perez E.M., Hernandez D., Miller C.P., Haas K.M.,
RA   Irie H.Y., Lee S.-I., Blau C.A., Villen J.;
RT   "The proteomic landscape of triple-negative breast cancer.";
RL   Cell Rep. 11:630-644(2015).
RX   PubMed=25960936; DOI=10.4161/21624011.2014.954893;
RA   Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.;
RT   "A catalog of HLA type, HLA expression, and neo-epitope candidates in
RT   human cancer cell lines.";
RL   OncoImmunology 3:e954893.1-e954893.12(2014).
RX   PubMed=26055192; DOI=10.1021/acs.jproteome.5b00375;
RA   Cifani P., Kirik U., Waldemarson S., James P.;
RT   "Molecular portrait of breast-cancer-derived cell lines reveals poor
RT   similarity with tumors.";
RL   J. Proteome Res. 14:2819-2827(2015).
RX   PubMed=26218769; DOI=10.1016/j.jchromb.2015.07.021;
RA   Willmann L., Schlimpert M., Halbach S., Erbes T., Stickeler E.,
RA   Kammerer B.;
RT   "Metabolic profiling of breast cancer: differences in central
RT   metabolism between subtypes of breast cancer cell lines.";
RL   J. Chromatogr. B 1000:95-104(2015).
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
RX   PubMed=28287265; DOI=10.1021/acs.jproteome.6b00470;
RA   Yen T.-Y., Bowen S., Yen R., Piryatinska A., Macher B.A., Timpe L.C.;
RT   "Glycoproteins in claudin-low breast cancer cell lines have a unique
RT   expression profile.";
RL   J. Proteome Res. 16:1391-1400(2017).
RX   PubMed=28596718; DOI=10.1007/s11306-017-1213-z;
RA   Herman S., Emami Khoonsari P., Aftab O., Krishnan S., Strombom E.,
RA   Larsson R., Hammerling U., Spjuth O., Kultima K., Gustafsson M.;
RT   "Mass spectrometry based metabolomics for in vitro systems
RT   pharmacology: pitfalls, challenges, and computational solutions.";
RL   Metabolomics 13:79-79(2017).
RX   PubMed=28889351; DOI=10.1007/s10549-017-4496-x;
RA   Saunus J.M., Smart C.E., Kutasovic J.R., Johnston R.L.,
RA   Kalita-de Croft P., Miranda M., Rozali E.N., Vargas A.C., Reid L.E.,
RA   Lorsy E., Cocciardi S., Seidens T., McCart Reed A.E., Dalley A.J.,
RA   Wockner L.F., Johnson J., Sarkar D., Askarian-Amiri M.E.,
RA   Simpson P.T., Khanna K.K., Chenevix-Trench G., Al-Ejeh F.,
RA   Lakhani S.R.;
RT   "Multidimensional phenotyping of breast cancer cell lines to guide
RT   preclinical research.";
RL   Breast Cancer Res. Treat. 167:289-301(2018).
RX   PubMed=29273624; DOI=10.1101/gr.226019.117;
RA   Franco H.L., Nagari A., Malladi V.S., Li W.-Q., Xi Y.-X., Richardson D.,
RA   Allton K.L., Tanaka K., Li J., Murakami S., Keyomarsi K.,
RA   Bedford M.T., Shi X.-B., Li W., Barton M.C., Dent S.Y.R., Kraus W.L.;
RT   "Enhancer transcription reveals subtype-specific gene expression
RT   programs controlling breast cancer pathogenesis.";
RL   Genome Res. 28:159-170(2018).
RX   PubMed=29444910; DOI=10.1530/ERC-17-0445;
RA   Hofving T., Arvidsson Y., Almobarak B., Inge L., Pfragner R.,
RA   Persson M., Stenman G., Kristiansson E., Johanson V., Nilsson O.;
RT   "The neuroendocrine phenotype, genomic profile and therapeutic
RT   sensitivity of GEPNET cell lines.";
RL   Endocr. Relat. Cancer 25:367-380(2018).
RX   PubMed=29561695; DOI=10.1080/15384047.2018.1449612;
RA   Chen Z.-J., Ai L.-B., Mboge M.Y., McKenna R., Frost C.J., Heldermon C.D.,
RA   Frost S.C.;
RT   "UFH-001 cells: a novel triple negative, CAIX-positive, human breast
RT   cancer model system.";
RL   Cancer Biol. Ther. 19:598-608(2018).
RX   PubMed=30787054; DOI=10.1158/1055-9965.EPI-18-1132;
RA   Hooker S.E. Jr., Woods-Burnham L., Bathina M., Lloyd S., Gorjala P.,
RA   Mitra R., Nonn L., Kimbro K.S., Kittles R.A.;
RT   "Genetic ancestry analysis reveals misclassification of commonly used
RT   cancer cell lines.";
RL   Cancer Epidemiol. Biomarkers Prev. 28:1003-1009(2019).
RX   PubMed=32782317; DOI=10.1038/s41598-020-70393-4;
RA   Risha Y., Minic Z., Ghobadloo S.M., Berezovski M.V.;
RT   "The proteomic analysis of breast cell line exosomes reveals disease
RT   patterns and potential biomarkers.";
RL   Sci. Rep. 10:13572-13572(2020).
RX   PubMed=34238275; DOI=10.1186/s12885-021-08511-2;
RA   Samson J., Derlipanska M., Zaheed O., Dean K.;
RT   "Molecular and cellular characterization of two patient-derived ductal
RT   carcinoma in situ (DCIS) cell lines, ETCC-006 and ETCC-010.";
RL   BMC Cancer 21:790.1-790.20(2021).